CHTF
6.8.2024 03:01:29 CEST | Business Wire | Press release
The 26th China Hi-tech Fair (CHTF2024) will take place on November 14-16, 2024 in Shenzhen China. This year’s fair promises to be a groundbreaking event, covering approximately 400,000m2 and attracting over 5,000 renowned enterprises and international organizations from more than 100 countries and regions. CHTF2024 will feature multiple exhibition zones covering AI and robotics, clean energy, high-end medical devices, China’s leading heavy equipment, top tech industry chains, etc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802870555/en/
Global Buyer Invitation Programme of the 26th China Hi-tech Fair (CHTF2024) (Graphic: Business Wire)
China has solidified its position as a global technology powerhouse, with significant advancements in AI, big data, 5G, and clean energy. CHTF serves as a vital platform for debuting innovations and facilitating exchanges. In 2024, the ultimate platform invites global powerful exhibitors to win business for innovation in China’s huge tech market.
To ensure the maximum value for exhibitors, buyers, and visitors, CHTF has launched a comprehensive Global Buyer Invitation Programme, which will invite nearly 500 international buyer delegations from Europe, America, Southeast Asia, the Middle East, and other regions. The anticipated 500,000 professional visitors will create an unparalleled opportunity for business growth and networking.
Key Highlights of The Programme:
- International and Domestic Buyer Delegations: The event collaborates with prestigious buyer delegations formed by state-owned enterprises, industry leaders, and international corporations, including PetroChina (CNPC), China National Offshore Oil Corporation (CNOOC), CIPR-The conference “Digitalization of Industrial Russia”, Australian Trade & Investment Commission, etc.
- Tailored Matchmaking: Customized procurement matchmaking events and industry-specific conferences will be held to cater to the precise needs of domestic and international buyers.
- Extensive Buyer Outreach: The organizer will collect the specific procurement requirements of high-quality buyers in advance and meticulously select qualified exhibitors to ensure that the matchmaking process is precise and effective.
- Exclusive Buyer Benefits: The registered purchasers can enjoy a range of perks, including VIP privileges, streamlined entry, pre-arranged meetings with exhibitors, complimentary gifts and meals, transportation, and hotel accommodations, and additionally, a chance of lucky draw for signing contracts on-site. (Buyer benefits are subject to change without notice. Please consult the organizer for details.)
With unwavering Shenzhen government backing, extensive industry support, and proven track records of success, CHTF2024 is poised to be the premier destination to explore cutting-edge technologies, foster business collaborations, and contribute to the future of global industries.
Exhibitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/exhibit-apply.html?EID=E0000000413&target=4&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Visitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/vistor-register.html?EID=E0000000413&target=1&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Follow us on Facebook/LinkedIn/X for updates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802870555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom